Alnylam Pharmaceuticals stock hits all-time high at 445.44 USD

Alnylam Pharmaceuticals Inc. stock reached an all-time high of 445.44 USD, marking a significant milestone for the company. According to InvestingPro data, the stock appears overvalued at current levels, with analysts setting price targets ranging from $236 to $570. This achievement comes as the stock has experienced a substantial 1-year change, appreciating by 65.4%. The company’s robust performance includes impressive revenue growth of 5.01% and a strong gross profit margin of 83.64%. InvestingPro analysis reveals 16 additional key insights about Alnylam’s performance and future prospects. Investors appear optimistic about Alnylam’s future prospects, contributing to the stock’s impressive rise to its highest level in history. This optimism is supported by 13 analysts revising their earnings estimates upward, with expectations of profitability in the coming year.

In other recent news, Alnylam Pharmaceuticals reported second-quarter earnings that significantly exceeded analyst expectations. The company posted adjusted earnings of $0.32 per share, surpassing the consensus estimate of -$0.59. Revenue for the quarter reached $773.7 million, well above the projected $643.2 million, with a 64% year-over-year increase in total net product revenues, largely driven by Amvuttra’s success in ATTR cardiomyopathy. Additionally, Oppenheimer upgraded Alnylam’s stock to Outperform, citing stronger-than-expected sales of Amvuttra, which generated approximately $150 million in its first full quarter, far exceeding Oppenheimer’s estimate of $10 million and the consensus forecast of $17 million. Wolfe Research also upgraded Alnylam’s stock rating to Peerperform, attributing the decision to the company’s better-than-expected patient acquisition capabilities. These recent developments highlight Alnylam’s robust performance in the biopharmaceutical sector.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.